Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;186(1):4-5.
doi: 10.1111/bjd.20813. Epub 2021 Nov 2.

Risankizumab vs. fumaric acid esters: a direct comparison

P Fleming  1
Affiliations
Comment

Risankizumab vs. fumaric acid esters: a direct comparison

P Fleming. Br J Dermatol. 2022 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl. 2):2-9.
    1. Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392:650-61.
    1. Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418-31.
    1. Balak DM. Fumaric acid esters in the management of psoriasis. Psoriasis (Auckl) 2015; 5:9-23.
    1. Thaçi D, Eyerich K, Pinter A et al. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naive patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. Br J Dermatol 2022; 186:30-9.